The trajectory of companies tied to the drug's legacy presents a complex investment scenario . While the initial boom generated substantial returns , generic copies have significantly eroded revenue. Investing in associated pharmaceutical firms now requires a discerning assessment of intellectual property protection , evolving medical changes, and